Stock AnalizNovavax Inc. NVAX
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Novavax Inc. (NVAX) is a healthcare company listed in the US with a market value of about $1.4B. In the twelve months to September 30, 2026 it had revenue of $412M and net income of -$77M, a net margin of -18.6%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 19% a year.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $412M | $1.1B | $682M | $984M | $2.0B | $1.1B | $476M | $19M | $34M | $31M | $15M |
| Net income | -$77M | $440M | -$187M | -$545M | -$658M | -$1.7B | -$418M | -$133M | -$185M | -$184M | -$280M |
| Free cash flow | -$243M | -$250M | -$100M | -$768M | -$505M | $265M | -$97M | -$138M | -$186M | -$149M | -$277M |
| EPS (diluted) | $-0.47 | $2.58 | $-1.23 | $-5.41 | $-8.42 | $-23.44 | $-7.27 | $-5.51 | $-9.99 | $-12.56 | $-20.60 |
| Net margin | -18.6% | 39.2% | -27.5% | -55.4% | -33.2% | -152.1% | -87.9% | -711.0% | -538.8% | -589.5% | -1823.5% |
| ROIC | — | — | — | — | — | — | -52.9% | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $14.11, 66% above the current price; targets range from $7.00 to $25.00; the consensus rating is “Buy”; expected EPS is $-0.05 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Novavax pay a dividend?
Not currently.
Is Novavax a good stock to buy?
We do not give buy or sell advice. Novavax scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.